Abbott Laboratories

ABT · NYSE

$102.45−$1.61 (−1.55%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $104.06

ABT analyst rating

BuyConsensus of 20 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy20
Hold0
Underperform0
Sell0

12-month price target · 28 analysts

Average $123.39 (+20.4% upside)

Low: $104.03
Now: $102.45
High: $142.80

Upgrades and downgrades

The latest rating actions, newest first

ABT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
TD Cowen	Oct 16, 2026	Maintains	Buy	$135.00	48%
Barclays	Oct 7, 2026	Initiates	Overweight	$120.00	57%
Rothschild & Co	Oct 2, 2026	Upgrade	Neutral → Buy	$119.00 → $127.00	33%
TD Cowen	Sep 8, 2026	Maintains	Buy	$135.00	48%
TD Cowen	Aug 21, 2026	Maintains	Buy	$115.00 → $135.00	48%
Citigroup	Aug 14, 2026	Maintains	Buy	$112.00 → $125.00	60%
Wolfe Research	Aug 13, 2026	Upgrade	Peer Perform → Outperform	$130.00	45%
UBS	Jul 28, 2026	Maintains	Buy	$135.00 → $125.00	43%
Citigroup	Jul 17, 2026	Maintains	Buy	$108.00 → $112.00	60%
Piper Sandler	Jul 17, 2026	Maintains	Overweight	$115.00 → $118.00	51%

The case for and against

Updated Oct 14, 2026

Bull case

Abbott Laboratories is well positioned for durable outperformance because its diversified portfolio spans high-need categories like cardiovascular devices, diabetes care, diagnostics, nutrition, and branded generics, with roughly 60% of sales generated outside the United States. Recent results reinforced that view, as 2Q'26 revenue of $12.59B and EPS of $1.31 beat expectations, comparable sales rose 4.8%, gross margin expanded to 58.0%, and management raised 2026 adjusted EPS guidance to $5.45-$5.60 while reaffirming 6.5%-7.5% comparable sales growth. Its outlook is further supported by catalyst-rich innovation, including FDA approval for TactiFlex Duo, strong FlexPulse data with 74.6% composite effectiveness and a 1.7% adverse event rate, and a 2027 framework for about 7% organic revenue growth and double-digit EPS growth.

Bear case

Abbott Laboratories is facing a negative setup because its core businesses are exposed to pricing pressure in global adult and pediatric Nutrition, along with pricing and procedure volume pressure in Medical Devices that can weigh on revenue and margins. Regulatory timing for approvals in Medical Devices and Diagnostics, plus the challenge of forecasting demand for hundreds of product launches in emerging markets within Established Pharmaceuticals, adds execution risk and makes growth less predictable. Its roughly 60% international revenue base also increases vulnerability to foreign exchange swings, inflationary headwinds, supply chain disruptions, and macro weakness that could offset COVID-19 testing gains or higher competition.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.